Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14777605 | 1.00 | REN (0.47) | REN | |
| SCHEMBL2568835 | 0.86 | LDHA (0.55) | — | |
| SCHEMBL31666050 | 0.86 | LDHA (0.55) | — | |
| SCHEMBL2575301 | 0.86 | LDHA (0.55) | — | |
| SCHEMBL253884 | 0.86 | FOS (0.49) | REN | |
| SCHEMBL3914703 | 0.85 | REN (0.52) | REN | |
| SCHEMBL3912919 | 0.85 | REN (0.52) | REN | |
| SCHEMBL2438095 | 0.85 | REN (0.47) | REN | |
| SCHEMBL220393 | 0.83 | MEN1 (0.47) | REN | |
| SCHEMBL14114916 | 0.82 | ALOX15 (0.55) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | claimed |
| EP-2576500-A2 | PROCESS FOR PRODUCING ALISKIREN | Chemo Iberica, S.A. (ES) | 2013-04-10 | — | — | EP | claimed |
| US-20130071899-A1 | Process for Producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2013-03-21 | — | — | US | claimed |
| US-8088954-B2 | Preparation of a saturated aldehyde | DSM IP ASSETS B.V. (NL) | 2012-01-03 | — | — | US | claimed |
| WO-2011151442-A2 | PROCESS FOR PRODUCING ALISKIREN | CHEMO IBERICA, S.A. (ES) | 2011-12-08 | — | — | WO | claimed |
| CN-101801903-A | Preparation of a saturated aldehyde | DSM IP ASSETS BV | 2010-08-11 | — | — | CN | claimed |
| US-20100197972-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP ASSETS B.V. (NL) | 2010-08-05 | — | — | US | claimed |
| EP-2173696-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP Assets B.V. (NL) | 2010-04-14 | — | — | EP | claimed |
| WO-2009007461-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP ASSETS B.V. (NL) | 2009-01-15 | — | — | WO | claimed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-20130252288-A1 | ENANTIOSELECTIVE REDUCTION | DSM IP ASSETS B.V. (NL) | 2013-09-26 | — | — | US | disclosed |
| US-20130071899-A1 | Process for Producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2013-03-21 | — | — | US | disclosed |
| US-8088954-B2 | Preparation of a saturated aldehyde | DSM IP ASSETS B.V. (NL) | 2012-01-03 | — | — | US | disclosed |
| US-8088955-B2 | Alpha-substituted α,β-unsaturated E- or Z-aldehydes, use thereof, and processes for their preparation α,β | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG (AT) | 2012-01-03 | — | — | US | disclosed |
| CN-101801903-A | Preparation of a saturated aldehyde | DSM IP ASSETS BV | 2010-08-11 | — | — | CN | disclosed |
| US-20100197972-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP ASSETS B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| EP-2173696-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP Assets B.V. (NL) | 2010-04-14 | — | — | EP | disclosed |
| EP-2171077-A2 | ENANTIOSELECTIVE REDUCTION | DSM IP Assets B.V. (NL) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009007460-A2 | ENANTIOSELECTIVE REDUCTION | DSM IP ASSETS B.V. (NL) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007461-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP ASSETS B.V. (NL) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197972-A1 | PREPARATION OF A SATURATED ALDEHYDE | H1-0, F9, HRH4 | REN 112/4885 |
| US-20130071899-A1 | Process for Producing Aliskiren | REN, AGTR1, AGTR2 | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.